261780 — CHA Vaccine Research Institute Balance Sheet
0.000.00%
- KR₩81bn
- KR₩50bn
- KR₩371m
Annual balance sheet for CHA Vaccine Research Institute, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 24,827 | 61,550 | 57,763 | 38,896 | 40,107 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 188 | 267 | 608 | 454 | 400 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 25,037 | 61,847 | 58,917 | 42,486 | 44,590 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 587 | 1,032 | 1,543 | 1,644 | 1,120 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 25,747 | 65,313 | 61,069 | 45,119 | 47,248 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,806 | 24,706 | 26,789 | 810 | 9,613 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 24,174 | 25,698 | 27,703 | 9,702 | 19,526 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1,573 | 39,615 | 33,366 | 35,417 | 27,722 |
Total Liabilities & Shareholders' Equity | 25,747 | 65,313 | 61,069 | 45,119 | 47,248 |
Total Common Shares Outstanding |